What is the appropriate evaluation and management approach for an adult male with symptoms of hypogonadism, such as low libido, fatigue, or decreased muscle mass?

Evaluation and Management of Adult Male Hypogonadism

Diagnostic Confirmation

Diagnosis requires both biochemical confirmation with two separate morning (8-10 AM) total testosterone measurements below 300 ng/dL AND the presence of specific hypogonadal symptoms—particularly diminished libido and erectile dysfunction. 1, 2

Initial Laboratory Workup

• Measure morning total testosterone on two separate occasions between 8-10 AM to establish persistent hypogonadism, as single measurements are insufficient due to assay variability and diurnal fluctuation 1, 2
• Obtain free testosterone by equilibrium dialysis in men with obesity, diabetes, or borderline total testosterone (231-346 ng/dL), as SHBG alterations can mask true hypogonadism 2
• Measure SHBG levels to distinguish true hypogonadism from SHBG-related decreases in total testosterone 1, 2

Distinguishing Primary from Secondary Hypogonadism

Once low testosterone is confirmed, measure serum LH and FSH to determine the type of hypogonadism, which has critical treatment implications for both fertility preservation and treatment selection 1, 2:

• Elevated LH/FSH with low testosterone = Primary (testicular) hypogonadism 2
• Low or low-normal LH/FSH with low testosterone = Secondary (hypothalamic-pituitary) hypogonadism 2

This distinction is critical because secondary hypogonadism patients can potentially achieve both fertility restoration and normal testosterone with gonadotropin therapy, whereas primary hypogonadism patients can only receive testosterone therapy, which permanently compromises fertility. 1, 2

Additional Workup for Secondary Hypogonadism

• Measure serum prolactin to investigate for hyperprolactinemia 2, 3
• Obtain iron saturation to exclude hemochromatosis 2
• Consider pituitary MRI if prolactin is elevated or other pituitary dysfunction is suspected 2, 3

---

Treatment Selection Algorithm

Step 1: Assess Fertility Desires

Testosterone therapy is absolutely contraindicated in men actively seeking fertility preservation, as it causes azoospermia. 1, 2, 4

• If fertility preservation is desired: Use gonadotropin therapy (recombinant hCG plus FSH) as first-line treatment for secondary hypogonadism 1, 2
• If fertility is not a concern: Proceed with testosterone replacement therapy 1, 2

Step 2: Exclude Absolute Contraindications

Testosterone therapy is contraindicated in men with 1, 2, 4:

• Active or treated male breast cancer
• Prostate cancer (though evidence is evolving)
• Hematocrit >54%
• Untreated severe obstructive sleep apnea
• Recent cardiovascular events within 3-6 months

Step 3: Choose Testosterone Formulation

Transdermal testosterone gel (1.62% at 40.5 mg daily) is the preferred first-line formulation due to more stable day-to-day testosterone levels and lower risk of erythrocytosis compared to injectable preparations 1, 2:

Alternative formulations 2, 4:

• Intramuscular testosterone cypionate or enanthate: 100-200 mg every 2 weeks (or 50-100 mg weekly), more economical at $156/year vs $2,135/year for transdermal, but higher erythrocytosis risk
• Testosterone undecanoate: 750 mg initially, repeat at 4 weeks, then every 10 weeks—fewer injections but more expensive

Step 4: Address Obesity-Associated Hypogonadism

In men with obesity-associated secondary hypogonadism, attempt weight loss through low-calorie diets and regular exercise before initiating testosterone therapy, as this can improve testosterone levels without medication 1, 2

---

Expected Treatment Outcomes

Realistic Benefits

Testosterone therapy produces small but significant improvements in sexual function and libido (standardized mean difference 0.35), with modest quality of life improvements primarily in sexual function domains. 2

Testosterone therapy provides little to no effect on 2:

• Physical functioning
• Energy and vitality (SMD 0.17)
• Depressive symptoms (SMD -0.19)
• Cognition

Metabolic Benefits

• Improvements in fasting plasma glucose, insulin resistance, triglyceride levels, and HDL cholesterol 2
• Potential improvement in bone mineral density 2
• May help correct mild anemia 2

---

Monitoring Requirements

Initial Monitoring

• Measure testosterone levels 2-3 months after treatment initiation and after any dose change 2
• For injectable testosterone (cypionate/enanthate): Measure levels midway between injections (days 5-7), targeting mid-normal values of 500-600 ng/dL 2
• For transdermal preparations: Measure levels 4-6 hours after morning application 2

Ongoing Monitoring (Every 6-12 Months Once Stable)

• Testosterone levels to ensure therapeutic range 2
• Hematocrit/hemoglobin: Withhold treatment if hematocrit >54% and consider phlebotomy in high-risk cases 1, 2, 4
• PSA levels in men over 40 years: Refer for urologic evaluation if PSA increases >1.0 ng/mL in first 6 months or >0.4 ng/mL per year thereafter 2
• Digital rectal examination to assess for prostate abnormalities 2
• Clinical symptom response, particularly sexual function and libido 2

Treatment Reassessment

Reevaluate symptoms at 12 months and discontinue testosterone if no improvement in sexual function is seen, to prevent unnecessary long-term exposure to potential risks without benefit 2

---

Alternative Treatment: Clomiphene Citrate

For men with secondary hypogonadism who desire fertility preservation, clomiphene citrate (25-50 mg three times weekly) is an effective off-label alternative that stimulates endogenous testosterone production without suppressing spermatogenesis 2, 5:

Advantages of Clomiphene

• Preserves fertility by maintaining or improving spermatogenesis 5
• Lower risk of polycythemia compared to testosterone 5
• More cost-effective than transdermal testosterone 5
• Achieves similar or superior outcomes for sexual function and quality of life 5

When to Switch from Clomiphene to Testosterone

• Primary hypogonadism is present (elevated LH/FSH) 5
• Secondary hypogonadism fails to respond to clomiphene after 3 months 5
• Fertility preservation is no longer a concern 5

---

Critical Pitfalls to Avoid

• Never start testosterone without confirming the patient does not desire fertility, as suppression of spermatogenesis can be prolonged 1, 2
• Never diagnose hypogonadism based on symptoms alone without biochemical confirmation with two low morning testosterone measurements 1, 2
• Never use testosterone therapy in eugonadal men (normal testosterone levels), even for weight loss, cardiometabolic improvement, cognition, vitality, or physical strength 1, 2
• Never draw testosterone levels at peak (days 2-5) or trough (days 13-14) for injectable preparations, as this leads to inappropriate dosing adjustments 2
• Never assume age-related decline in young men—always investigate for secondary causes of hypogonadism, as reversible conditions must be addressed first 2
• Do not expect meaningful improvements in energy, physical function, or cognition, even with confirmed hypogonadism, as evidence shows minimal benefit 2